The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Low-dose pembrolizumab with chemotherapy in advanced NSCLC: a Phase III randomized trial
Nandini Menon, MBBS, MD, DNB, Tata Memorial Centre, Mumbai, India, discusses the results of a Phase III trial investigating the efficacy of low-dose pembrolizumab combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) lacking driver mutations. Dr Menon highlights that the addition of low-dose pembrolizumab to chemotherapy significantly improved overall survival (OS), with a median OS of 13.4-13.5 months compared to 10.47 months with chemotherapy alone, resulting in a 12.9% absolute benefit at one year. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
